What Is Prevnar 13?

Español | Prescribing Information

Prevnar 13® Home What Is Prevnar 13®? Can It Help Protect My Child Against IPD? How Can Pneumococcal Meningitis Affect
My Child? Is My Child at Risk for Invasive Pneumococcal Disease? What Diseases Can Pneumococcus Cause? Vaccination Schedule for Prevnar 13® The Importance of All 4 Doses of Prevnar 13® Important Safety Information for Prevnar 13® Prescribing Information Resources for Parents Helping to Improve the Vaccination Experience Facts About Vaccination Mobile App for Parents

FAQs

About the Importance of Vaccination with Prevnar 13®

GET THE ANSWERS

Mobile App for Parents

Download a useful mobile app that you can use to entertain your child during doctor's visits

LEARN MORE

Prevnar 13® is a vaccine that is indicated for children 6 weeks through 5 years of age, and it helps protect against 13 of the most common strains of pneumococcal bacteria that cause IPD, such as pneumococcal meningitis, today.

According to the Centers for Disease Control and Prevention (CDC), which children should be vaccinated with Prevnar 13®?

Children 2 months to 5 years of age
Children 15 months to 5 years who have already received 4 doses of Prevnar® (Pneumococcal 7-valent Conjugate Vaccine [Diphtheria CRM₁₉₇ Protein]) can get coverage from the additional serotypes in Prevnar 13® with one additional dose.

The immune response from this dose of Prevnar 13® might be lower for the 6 additional strains (types 1, 3, 5, 6A, 7F, and 19A) than if your child had received the full 4 doses of Prevnar 13®.
Prevnar® is a pediatric vaccine that was routinely given to infants and young children from 2000 until mid-2010 to help protect against 7 strains of pneumococcal bacteria.

Talk to your child’s doctor about the risks and benefits of Prevnar 13®. Only a health care provider can decide if Prevnar 13® is right for your child.

Home | Privacy Policy | Terms and Conditions | Contact Us | Sitemap

PREVNAR® and PREVNAR 13® are registered trademarks of Wyeth LLC.

The product information provided in this site is intended for residents of the United States. The products discussed herein may have different product labeling in different countries.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care provider, considering the unique characteristics of the patient.

SCROLL FOR INDICATIONS AND IMPORTANT SAFETY INFORMATION MORE

INDICATIONS FOR PREVNAR 13®

Prevnar 13® is a vaccine approved for use in children 6 weeks through 5 years for prevention of invasive disease (caused by the 13 strains of Streptococcus pneumoniae included in the vaccine) and ear infections (caused by 7 of the 13 strains)
Based upon immune responses to the vaccine, Prevnar 13® is also approved for adults 50 years and older for the prevention of pneumococcal pneumonia and invasive disease caused by the 13 vaccine strains
Prevnar 13® is not 100% effective and will only help protect against the 13 strains included in the vaccine
Effectiveness when given less than 5 years after a pneumococcal polysaccharide vaccine is not known

IMPORTANT SAFETY INFORMATION FOR PREVNAR 13®

Prevnar 13® should not be given to anyone with a history of severe allergic reaction to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine
Children and adults with weakened immune systems (eg, HIV infection, leukemia) may have a reduced immune response
A temporary pause of breathing following vaccination has been observed in some infants born prematurely
The most commonly reported serious adverse events in children were bronchiolitis (an infection of the lungs) (0.9%), gastroenteritis (inflammation of the stomach and small intestine) (0.9%), and pneumonia (0.9%)
In infants and toddlers, the most common side effects were tenderness, redness or swelling at the injection site, irritability, decreased appetite, decreased or increased sleep, and fever
In adults, immune responses to Prevnar 13® were reduced when given with injected seasonal flu vaccine
In adults, the common side effects were pain, redness, or swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, chills, or rash
Ask your health care provider about the risks and benefits of Prevnar 13®. Only a health care provider can decide if Prevnar 13® is right for your child

Please see the full Prescribing Information for Prevnar 13®

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.

The above Prescribing Information is available in PDF (portable document format).
PDF files require Adobe Reader; click here to download this free program.